Title |
On the role of the immunoproteasome in transplant rejection
|
---|---|
Published in |
Immunogenetics, September 2018
|
DOI | 10.1007/s00251-018-1084-0 |
Pubmed ID | |
Authors |
Michael Basler, Jun Li, Marcus Groettrup |
Abstract |
The immunoproteasome is expressed in cells of hematopoietic origin and is induced during inflammation by IFN-γ. Targeting the immunoproteasome with selective inhibitors has been shown to be therapeutically effective in pre-clinical models for autoimmune diseases, colitis-associated cancer formation, and transplantation. Immunoproteasome inhibition prevents activation and proliferation of lymphocytes, lowers MHC class I cell surface expression, reduces the expression of cytokines of activated immune cells, and curtails T helper 1 and 17 cell differentiation. This might explain the in vivo efficacy of immunoproteasome inhibition in different pre-clinical disease models for autoimmunity, cancer, and transplantation. In this review, we summarize the effect of immunoproteasome inhibition in different animal models for transplantation. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 34 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 5 | 15% |
Student > Master | 5 | 15% |
Student > Bachelor | 4 | 12% |
Researcher | 3 | 9% |
Lecturer > Senior Lecturer | 2 | 6% |
Other | 4 | 12% |
Unknown | 11 | 32% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 8 | 24% |
Agricultural and Biological Sciences | 3 | 9% |
Immunology and Microbiology | 2 | 6% |
Medicine and Dentistry | 2 | 6% |
Unspecified | 1 | 3% |
Other | 7 | 21% |
Unknown | 11 | 32% |